We are deeply saddened to learn that a patient participating in the non-ambulatory cohort of our Phase 1b mini-dystrophin gene therapy trial for Duchenne muscular dystrophy has passed away. On behalf of everyone at Pfizer, we extend our sympathies to his family, friends and those closest to his care.

At this time, we do not yet have complete information and are actively working with the trial site investigator to understand what happened. Screening and dosing in our Phase 1b clinical trial have been paused and we are working closely with the independent External Data Monitoring Committee to review the data. Regulators have been notified and the U.S. FDA has placed the Investigational New Drug (IND) Application on clinical hold. The safety and well-being of the patients in our clinical trial remains our top priority, and we are committed to sharing more information with the medical and patient community as soon as we can.

Sincerely,

The Pfizer DMD gene therapy team